Compare Incyte Corporation (INCY) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SAP SE — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while SAP SE trades at $155.04 (market cap $183.83B). The key difference: SAP SE is far larger — about 8× Incyte Corporation's market cap, and SAP SE pays a 1.85% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SAP | |
|---|---|---|
Market Cap | $23.11B | $183.83B |
Sector | Health | Technology |
52-Week High | $118.52 | $307.27 |
52-Week Low | $67.38 | $148.06 |
Enterprise Value | $19.13B | $181.35B |
Dividend Yield | — | 1.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SAP trades at $158.40, down 0.4% today, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 earnings of $2.01 per share, beating estimates, and maintains robust profitability with a 19.58% net income margin. Recent news highlights SAP's focus on AI investments and cost discipline, while EU antitrust concerns were resolved with concessions. Cash flow from operations remains strong at $9.16 billion for 2025, though net cash flow was negative $1.39 billion due to financing activities.
SAP presents a favorable risk-reward profile with a consensus price target of $222.33, implying significant upside. Analyst sentiment is bullish with 53.49% buy ratings. Key risks include competitive pressures in enterprise software and macroeconomic sensitivity. The stock's current valuation at a P/E of 22.38 offers a discount to growth prospects, supported by consistent earnings beats and strategic AI initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
